Bausch+Lomb Results Presentation Deck
YTD Total Bausch + Lomb P&L¹ (GAAP)
Bausch + Lomb
Vision Care Revenue³
Surgical Revenue
Pharmaceuticals Revenue ³
Total Revenue
Gross Profit
Gross Margin
R&D
R&D % of Revenues
SG&A
SG&A % of Revenues
Operating Income
Net (Loss) Income Attributable to Bausch
+ Lomb
Net (Loss) Income Margin
EPS Attributable to Bausch + Lomb
BAUSCH+ LOMB
1Q23-2Q23
$1,233M
$378M
$355M
$1,966M
$1,064 M
54.1%
$162M
8.2%
$835M
42.5%
$41M
($122M)
(6.2%)
($0.35)
1Q22-2Q224
$1,148M
$358M
$324M
$1,830M
$974M
53.2%
$152M
8.3%
$711M
38.9%
$110M
$25M
1.4%
$0.07
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
Reported Change Constant Currency Change²
10%
8%
12%
10%
12%
7%
6%
10%
7%
9%
90 bps
(7%)
(17%)
(7%)
(20%)
3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results
of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net
impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
4. YTD 2022 results were not fully burdened by all stand-up costs associated with the separation
29View entire presentation